Can Catalent Inc (CTLT)’s Tomorrow be Different? The Stock Just Broke Its High

October 12, 2017 - By Migdalia James

Investors sentiment increased to 2.13 in 2017 Q2. Its up 0.71, from 1.42 in 2017Q1. It improved, as 18 investors sold Catalent Inc shares while 50 reduced holdings. 51 funds opened positions while 94 raised stakes. 123.80 million shares or 2.01% less from 126.34 million shares in 2017Q1 were reported.
37,500 were reported by Art Advisors Lc. Los Angeles Cap Equity reported 0% in Catalent Inc (NYSE:CTLT). Fil Limited invested in 0.04% or 388,519 shares. Citigroup accumulated 86,611 shares or 0% of the stock. Loomis Sayles L P has invested 0.07% in Catalent Inc (NYSE:CTLT). Hanseatic Mgmt reported 11,861 shares. Advisory Serv Net Ltd Liability Co owns 97 shares. Eaton Vance Mngmt reported 186,000 shares or 0.02% of all its holdings. 1.15 million are held by Thrivent For Lutherans. Credit Suisse Ag has invested 0% of its portfolio in Catalent Inc (NYSE:CTLT). Profund Limited Liability Company holds 21,202 shares. Voya Invest Limited Liability Corporation reported 0.07% in Catalent Inc (NYSE:CTLT). Natixis stated it has 0.02% of its portfolio in Catalent Inc (NYSE:CTLT). Alliancebernstein Lp stated it has 0.01% in Catalent Inc (NYSE:CTLT). Franklin Res reported 3.40 million shares.

The stock of Catalent Inc (NYSE:CTLT) hit a new 52-week high and has $43.48 target or 3.00 % above today’s $42.21 share price. The 9 months bullish chart indicates low risk for the $5.34 billion company. The 1-year high was reported on Oct, 12 by If the $43.48 price target is reached, the company will be worth $160.20M more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock.

About 107,619 shares traded. Catalent Inc (NYSE:CTLT) has risen 27.19% since October 12, 2016 and is uptrending. It has outperformed by 10.49% the S&P500.

Analysts await Catalent Inc (NYSE:CTLT) to report earnings on November, 6. They expect $0.17 EPS, up 41.67 % or $0.05 from last year’s $0.12 per share. CTLT’s profit will be $21.50 million for 62.10 P/E if the $0.17 EPS becomes a reality. After $0.64 actual EPS reported by Catalent Inc for the previous quarter, Wall Street now forecasts -73.44 % negative EPS growth.

Catalent Inc (NYSE:CTLT) Ratings Coverage

Among 13 analysts covering Catalent (NYSE:CTLT), 7 have Buy rating, 0 Sell and 6 Hold. Therefore 54% are positive. Catalent had 27 analyst reports since September 3, 2015 according to SRatingsIntel. The firm earned “Buy” rating on Wednesday, September 20 by Bank of America. Jefferies maintained the shares of CTLT in report on Monday, June 26 with “Hold” rating. The firm has “Sector Weight” rating given on Friday, September 8 by KeyBanc Capital Markets. The firm earned “Hold” rating on Wednesday, November 4 by Deutsche Bank. The firm earned “Buy” rating on Thursday, September 3 by Bank of America. The rating was initiated by Goldman Sachs on Thursday, December 1 with “Neutral”. The company was upgraded on Thursday, September 21 by Morgan Stanley. The rating was upgraded by Wells Fargo on Tuesday, June 21 to “Outperform”. The stock has “Hold” rating by Jefferies on Thursday, September 10. The rating was downgraded by Morgan Stanley to “Ewu” on Thursday, April 21.

More important recent Catalent Inc (NYSE:CTLT) news were published by: which released: “Catalent, Inc. Announces Pricing of Public Offering of Common Stock to Fund …” on September 27, 2017, also published article titled: “M&A News: Catalent Inc (CTLT) to Buy Cook Pharmica in $950M Deal”, published: “Catalent to Acquire Cook Pharmica for $950 Million” on September 19, 2017. More interesting news about Catalent Inc (NYSE:CTLT) was released by: and their article: “Catalent, Inc. Announces Public Offering of Common Stock to Fund Part of its …” with publication date: September 25, 2017.

Catalent, Inc. provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. The company has market cap of $5.34 billion. The Company’s divisions include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. It has a 48.86 P/E ratio. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.